The FDA has approved garadacimab-gxii for prophylactic use in patients aged 12 years and older with hereditary angioedema, ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused ...

BofA raised the firm’s price target on KalVista (KALV) to $37 from $22 and keeps a Buy rating on the shares after the company announced the approval of Ekterly for on-demand treatment of hereditary ...

H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health ...

Panelists discuss how patients with prior type 2 diabetes misdiagnosis showed significantly higher healthcare utilization rates across all categories (inpatient admissions, emergency visits, ...

The White House’s plans to make significant cuts to funding from NIH is expected to have significant impact on the pharma industry for years to come. Justin Kozak, an executive VP at Founder Shield, ...

DoorDash Inc. (NASDAQ:DASH) is one of the 12 best consumer goods stocks billionaires are quietly buying. On June 30, Oppenheimer reiterated an Outperform rating on the stock. The analyst also raised ...